Pinot Bio

What Pinot Bio does

Pinot Bio is a South Korea-based clinical-stage biotechnology company founded in 2017 as a spin-off from the Korea Institute of Chemical Technology (KRICT). The company develops next-generation oncology therapeutics, anchored by its proprietary PINOT-ADC™ platform — a modular antibody-drug conjugate (ADC) technology combining camptothecin-derived topoisomerase I (Top1) inhibitor payloads (PBX series) with a sequential-cleavable hydrophilic linker (PINOT-Linker) engineered to reduce off-target toxicity and interstitial lung disease (ILD) by more than half versus conventional GGFG linkers in primate models. The platform also supports dual-payload ADCs combining Top1 inhibitors (PBX-7016) with microtubule inhibitors (MMAE) and is compatible with multiple carrier modalities including antibodies, aptamers, and repebodies. Beyond the ADC platform, Pinot Bio is independently developing two clinical-stage assets: NTX-301, an oral nucleoside-based DNMT1 inhibitor that completed US Phase 1a in MDS/AML blood cancer (May 2024) and is now in Phase 1b/2a, and NTX-101, a first-in-class topical glaucoma treatment with dual IOP-lowering and optic nerve protection mechanism.

The company's business model is a B2B platform licensor: Pinot Bio monetizes PINOT-ADC through upfront payments, development and regulatory milestones, and royalties from pharmaceutical partners who develop, manufacture, and commercialize ADC products under their own brands. Anchor licensing deals include Celltrion (up to 15 targets, ~1.7 trillion KRW total deal value, two targets exercised including CT-P70 and CT-P71) and ConjugateBio (10 targets, ~320 billion KRW). Cumulative technology transfer value exceeds 2 trillion KRW. The company also secures non-dilutive capital through Korean government research grants (MOTIE, KDDF, KBIOHealth), including a 220 billion KRW MOTIE project running through 2028 for domestic ADC production localization. Pinot Bio operates from Suwon, South Korea with a North American subsidiary in California managing US clinical development and FDA communication. The team is approximately 29 employees with 75% in R&D, led by founder/CEO Jung Doo-young and supplemented by senior ex-big-pharma hires from Pfizer, AstraZeneca, GSK, and BMS. A KOSDAQ listing attempt was withdrawn in February 2024 due to market uncertainty, with management signaling a future re-listing at an optimal window.

Name

Pinot Bio

Legal name

(주)피노바이오

Website

https://pinotbio.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Pinot Bio is a South Korean clinical-stage biotech developing the proprietary PINOT-ADC™ antibody-drug conjugate platform and clinical assets NTX-301 (DNMT1 inhibitor for MDS/AML) and NTX-101 (glaucoma), licensing its technology to global pharmaceutical partners including Celltrion and ConjugateBio.

Ownership category

akta.pro rank

Product category

ADC Therapeutics Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Antibody-drug conjugates
• ADC platform technology
• Oncology drug pipeline
• Biotech R&D services
• Targeted cancer therapeutics

Headquarters

HQ city

Suwon

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Platform Technology Licensing & Milestones: Upfront payments, development milestones, regulatory milestones, and sales royalties from licensing PINOT-ADC platform technology to pharmaceutical partners. Key deals include Celltrion (up to 15 targets, total ~$1.24B/1.7T KRW, with 2 targets exercised) and ConjugateBio (10 additional targets, total ~$320B KRW). Cumulative technology transfer value exceeds 2 trillion KRW.
2. Government Research Grants: Funded R&D partnerships with Korean government ministries (MOTIE, KMES, KDDF, KBIOHealth) for ADC development, production localization, and linker technology. Includes 220B KRW MOTIE project for ADC production domestication by 2028 and 50B KRW MOTIE project for Trop2 ADC GMP manufacturing process development over 5 years.
3. Equity Financing: Pre-revenue biotech; raises capital through private placements and pre-IPO rounds from venture capital firms and strategic pharmaceutical investors. Has raised cumulative ~500B KRW across seed, Series A, B, C, and pre-IPO rounds.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

Core offering

Pinot Bio (피노바이오) is a Korea-based biotechnology company developing a proprietary antibody-drug conjugate (ADC) platform branded as PINOT-ADC™, alongside an internal pipeline of ADC therapeutic candidates including NTX-301 and NTX-101. The company operates R&D, pipeline, and investor relations functions consistent with a clinical-stage biotech developing targeted oncology therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• PINOT-ADC™: 차세대 ADC 항암제 플랫폼 기술로 기존 ADC 약물의 한계를 극복하는 독자적인 약물(Payload) 및 링커(Linker) 기술
• PINOT-Linker
• PBX-001
• PBX-7016

Products and services

• PINOT-ADC™
• NTX-301
• NTX-101

Quantifiable outcome

• Sequential-cleavable linker reduces drug release in normal tissue by ~10x vs. conventional single-enzyme linkers, and reduces uptake into normal (non-target) cells by >2x vs. existing systems
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered secondary, minor, flagship and core.

• KBIOHealth (오송첨단의료산업진흥재단)secondaryStrategic or Co-development Partner · 25 February 2025Government research collaboration on ADC production. Pinotbio serves as lead organization for MOTIE's 220 billion KRW ADC production domestication project running through December 2028. Three subprojects: ADC synthesis technology development (Pinotbio lead), large-scale active ingredient synthesis and purification (KBIOHealth + Kyungbo Pharmaceutical), and AI-based ADC manufacturing automation system (Nexa). KBIOHealth provides cell bank (KBIO-K1) and GMP production process development support. Part of longer collaboration on ADC GMP manufacturing process development since 2023.
• MediMapBio (메디맵바이오)minorStrategic or Co-development Partner · 31 October 2024MOU signed October 2024 for immuno-regulatory ADC development. Collaboration to develop a new class of ADCs with immune regulatory mechanisms using Pinotbio's ADC platform technology.
• TheraPaxminorStrategic or Co-development Partner · 2 May 2024Joint research collaboration for TPD-ADC (Targeted Protein Degradation ADC) anticancer drug development. Pinotbio provides its ADC platform (payload + linker); TheraPax contributes targeted protein degradation technology.
• ConjugateBioflagshipOEM/ Whitelabel/ Licensing Partner · 21 December 2023ADC platform technology transfer agreement expanded to 10 additional drug targets (total 15 targets including 2022 deal) with US biotech ConjugateBio. Pinotbio supplies payload and linker technology; ConjugateBio handles target selection, antibody development, synthesis, and evaluation. Deal value ~250 million dollars (~3,200억원) including upfront, milestones, and royalties. Founded by former Merck, Novartis, and Daiichi Sankyo executives. Pinotbio's second major platform licensing deal, bringing cumulative technology transfer value above 2 trillion KRW.
• Lotte BiologicscoreStrategic or Co-development Partner · 21 April 2023Strategic investment and ADC CDMO partnership. Lotte Biologics invested in Pinotbio to develop ADC platforms and establish strategic partnerships for ADC technology development and manufacturing via Lotte's Korean Mega Plant Campus. Investment is part of Lotte's Bio-Venture Initiative to support biotech startups and expand its ADC CDMO business. Pinotbio is collaborating with Lotte on ADC development and manufacturing using Lotte's production facilities.
• CelltrionflagshipOEM/ Whitelabel/ Licensing Partner · 1 October 2022Platform technology transfer and joint development agreement signed October 2022 for PINOT-ADC™ platform (payload + linker) across up to 15 ADC targets. Celltrion develops and commercializes ADC products using Pinotbio's platform. Deal value up to ~$1.24 billion (12억 4280만 달러/약 1조 7천억원) including upfront, milestones, and royalties. Celltrion exercised options on two targets: CT-P70 (cMET) for bladder cancer and CT-P71 (Nectin-4) for NSCLC. First milestone achieved September 2024. All options executed would total ~12억 달러. Pinotbio's PBX-7016 payload used in CT-P70 and CT-P71. Pinotbio also holds a strategic investment stake from Celltrion.
• Bridge BiotherapeuticsminorStrategic or Co-development Partner · 26 January 2022Partnership for developing cancer therapeutics using ADC technology. Bridge Biotherapeutics contributes its therapeutic development expertise; Pinotbio provides its PINOT-ADC platform.
• Aptamer GroupsecondaryStrategic or Co-development Partner · 7 July 2021Joint research collaboration for Aptamer-Drug Conjugate (ApDC) development. Initially focused on hematologic malignancies (lymphoma, myeloma, myeloma); expanded to four additional targets (Nectin-4, Tissue Factor, CEACAM5, CD73) in May 2022. Aptamer Group provides Optimer™ aptamer platform; Pinotbio provides its PINOT-ADC payload and linker technology. UK-listed biotech with partnerships with AstraZeneca and Takeda on ApDC development. Expanded collaboration announced May 2022.
• ProEn Therapeutics (프로엔테라퓨틱스)secondaryStrategic or Co-development Partner · 7 July 2021Strategic partnership for Repebody-Drug Conjugate development. ProEn Therapeutics provides its proprietary Repebody platform (novel class of immune proteins from fish with small size, high tumor penetration, and high EGFR binding affinity — 3x stronger than conventional antibodies). Pinotbio provides payload and linker technology. Joint research aimed at developing novel anticancer drug conjugates using the combined platforms.
• Aston Science (애스톤사이언스)minorStrategic or Co-development Partner · 22 July 2020Clinical co-development agreement for NTX-301 (blood cancer). Aston Science, a clinical development biotech founded by former MSD and SKbiopharma R&D professionals, provides clinical development expertise, infrastructure, and optimized patient recruitment for NTX-301 trials. Pinotbio retains all global rights to NTX-301.
• Clarivate AnalyticsminorStrategic or Co-development Partner · 23 August 2019Biomarker discovery partnership for NTX-301 using Clarivate's Cortellis platform and proprietary AI algorithms from the Computational Biology for Drug Discovery (CBDD) consortium. AI-powered analysis of 2 million+ curated datasets covering molecular interactions, biological pathways, disease biomarkers, and drug-cancer relationships to identify patient subgroups most likely to respond to NTX-301 treatment.

Scale indicators9 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Daiichi Sankyo: Japanese pharma major and inventor of the DXd Top1 inhibitor payload that underpins Enhertu and Datroway — the entrenched Top1-based ADC standard Pinotbio's PBX payload competes against. Daiichi Sankyo's ADC franchise is the gold standard Pinotbio benchmarks against in efficacy and safety, and any IP overlap in Top1 payload chemistry is a key risk factor.
• ImmunoGen (AbbVie): Pioneer of ADC platform technology (DM4 payload, cleavable linker) acquired by AbbVie in 2024 for $10.1B. Provides the canonical ADC platform M&A exit benchmark and validates the strategic value of differentiated payload + linker technology to large pharma. Important reference point for Pinotbio's long-term strategic optionality.

Direct peers

• LegoChem Biosciences: Korean biotech with proprietary ADC platform including its own linker chemistry (ConjuLink) and topoisomerase payloads — direct Korean-headquartered competitor pursuing the same next-gen ADC opportunity. Comparable business model (licensing platform to global pharma), similar stage of clinical maturity, and head-to-head competitor for Korean government ADC localization funding and Korean pharma partnerships.
• Mersana Therapeutics: US clinical-stage biotech developing next-generation ADCs with proprietary payload platforms (Dolasynthen, Immunosynthen) and linkers, including customizable DAR. Closest US-based comparable in business model (platform licensing, partner-funded development) and technical approach (payload + linker co-development). Validates the platform-licensing model Pinotbio employs.
• ProfoundBio: US-based clinical-stage ADC company developing proprietary payload and linker technologies including Top1 inhibitor-based ADCs with hydrophilic linkers. Recently acquired by Genmab. Highly comparable in technical approach (next-gen Top1 + hydrophilic linker) and a credible M&A exit benchmark for Pinotbio's platform.

Regional players

• ABL Bio: Korean biotech developing ADCs and bispecific antibodies with proprietary linker technology (Grabody) and targeting platforms. Strong Korean regional peer competing for the same Korean pharma partnerships (Celltrion, Lotte) and government grant funding. Listed on KOSDAQ, providing a public market comparable.

Emerging players

• Tubulis: German biotech developing proprietary ADC linker and payload technologies with focus on stability and bioconjugation chemistry. Closely comparable technical platform (novel linker + payload) at similar preclinical/early-clinical stage. Validates European pharma licensing appetite for differentiated ADC platforms.
• Pyxis Oncology: US clinical-stage ADC biotech with proprietary payload and linker platforms including microtubule-inhibitor and Top1-based payloads. Comparable technical approach (multiple payload classes + customizable DAR) and licensing/out-licensing business model. Listed on Nasdaq, providing public-market comparable for similar-stage ADC platform companies.
• Bolt Biotherapeutics: US clinical-stage biotech with proprietary immune-stimulating ADC (ISAC) platform combining tumor-targeting antibodies with immune agonists — adjacent ADC platform approach. Comparable in being a platform-licensing ADC company with proprietary payload chemistry and big-pharma partnership ambitions.
• MediLink Therapeutics: Emerging ADC platform company with proprietary payload and linker technologies, including Top1-based payloads, pursuing partnerships with global pharma. Asian-headquartered ADC platform peer with similar platform-licensing business model and partnership-driven revenue strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/embed/g5lMLoms9N8
• LinkedInlinkedin.com/company/bionetix-inc

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pinot Bio